DFB Pharmaceuticals
Practical innovations for life
banner-leaves.jpg

Partnering

Let's work together.

 

Long history of partnering success.


DFB has a long history of successfully partnering to develop and commercialize innovative technologies across a broad range of product categories and therapeutic areas.  We have operated as both seller or buyer, licensor or licensee, and believe in establishing mutually beneficial relationships that are designed for long-term success.

Available for license or sale

NANOLOGY LLC – locally delivered oncology drug PLATFORM

Our locally delivered large surface area microparticle (LSAM) investigational drugs are in clinical development in multiple solid tumor indications and related conditions. We have an extensive global IP portfolio including a composition of matter patent valid through 2036. Recently, we entered the expanding chemo-immunotherapy space and are conducting significant research to confirm the value of our investigational drugs in combination with immunoncology for the treatment of solid tumors. We intend to partner with a leading oncology company toward the regulatory approval of our investigational drugs.
Learn more about NanOlogy >

DOCETAXEL INJECTION USP (GENERIC EQUIVALENT TO TAXOTERE®)

Our FDA-approved docetaxel injection is available for distribution rights outside the USA. A generic to Taxotere®, our docetaxel injection is available in 20mg/mL, 80mg/4mL, and 200mg/10mL single use vials. Our API is supplied by the only producer in the world that does not rely on problematic 10-DAB as starting material for docetaxel API. Instead, the API used in our docetaxel injection is synthesized from a plant cell fermentation-derived starting material controlled start to finish in GMP facilities. 10-DAB, on the other hand, requires huge quantities of toxic solvents for extraction from non-GMP yew tree plantations, which are subject to weather and harvesting issues, most recently reported in 2015.

 
 
 

Contact Us